



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

July 25, 2022

Andrew Spaventa
Chief Executive Officer
Singular Genomics Systems, Inc.
3010 Science Park Road
San Diego, CA 92121

Re: Singular Genomics Systems, Inc.
Registration Statement on Form S-3
Filed July 19, 2022
File No. 333-266221

Dear Mr. Spaventa:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Ryan J. Gunderson